Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Ceapro Inc.
  6. Summary
    CZO   CA1499071076

CEAPRO INC.

(CZO)
  Report
Delayed Quote. Delayed Bourse de Toronto - 11/26 05:00:00 pm
0.58 CAD   +5.45%
11/18CEAPRO : 2021 Third Quarter Report
PU
11/17CEAPRO : Management Discussion and Analysis Q3 2021
PU
11/17CEAPRO : Interim Financial Statements Q3 2021
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Bourse De Toronto
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
0.57(c) 0.55(c) 0.53(c) 0.55(c) 0.58(c) Last
104 186 83 867 84 005 34 300 89 710 Volume
-3.39% -3.51% -3.64% +3.77% +5.45% Change
More quotes
Estimated financial data (e)
Sales 2019 12,9 M 10,1 M 10,1 M
Net income 2019 -1,13 M -0,88 M -0,88 M
Net Debt 2019 1,43 M 1,12 M 1,12 M
P/E ratio 2019 -21,8x
Yield 2019 -
Sales 2020 15,1 M 11,8 M 11,8 M
Net income 2020 1,86 M 1,45 M 1,45 M
Net cash position 2020 2,40 M 1,87 M 1,87 M
P/E ratio 2020 33,0x
Yield 2020 -
Capitalization 45,1 M 35,2 M 35,2 M
EV / Sales 2019 2,03x
EV / Sales 2020 3,23x
Nbr of Employees -
Free-Float 92,6%
More Financials
Company
Ceapro Inc. is a Canada-based biotechnology company. The Company's primary business activities relate to the development and marketing of various health and wellness products and technology relating to plant extracts. The Company operates through two segments: the active ingredient product technology industry and the cosmeceutical industry. The Company is engaged in the development of extraction technology and the... 
More about the company
All news about CEAPRO INC.
11/18CEAPRO : 2021 Third Quarter Report
PU
11/17CEAPRO : Management Discussion and Analysis Q3 2021
PU
11/17CEAPRO : Interim Financial Statements Q3 2021
PU
11/17Ceapro Books Higher Q3 Earnings, Reports Preliminary Results from Oat Beta Glucan Clini..
MT
11/17Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational..
AQ
11/17Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
11/17Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan ..
AQ
11/17Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan ..
CI
11/11Ceapro Provides Update on Development of an Inhalable Therapeutic
MT
11/11Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta..
AQ
11/11Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta..
CI
11/10Ceapro Inc. to Present at the Virtual Investor Roundtable Event
AQ
10/18CEAPRO INC.(TSXV : CZO) dropped from S&P/TSX Venture Composite Index
CI
09/08CEAPRO INC. : to Present at H.C. Wainwright 23rd Annual Global Investment Conference
AQ
08/26CEAPRO : 2021 Second Quarter Report
PU
More news
News in other languages on CEAPRO INC.
11/17Ceapro enregistre une hausse de ses bénéfices au troisième trimestre et publie les résu..
11/11Ceapro fait le point sur le développement d'un produit thérapeutique inhalable
08/26Ceapro annonce un bénéfice net de 0,01 $ par action au deuxième trimestre
08/23Ceapro entame une collaboration de recherche avec la Boston's Angiogenesis Foundation
More news
Chart CEAPRO INC.
Duration : Period :
Ceapro Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Gilles R. Gagnon President, Chief Executive Officer & Director
Stacy Prefontaine Chief Financial Officer & Secretary
Glenn R. Rourke Chairman
Bernhard Seifried Senior Director-Research & Technology
Paul Moquin Director-Scientific Affairs & Business Development
Sector and Competitors
1st jan.Capi. (M$)
CEAPRO INC.-12.12%35
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431